Search

Home > Diabetes Knowledge into Practice Podcast > First-line therapy in T2D | With Prof. David Matthews
Podcast: Diabetes Knowledge into Practice Podcast
Episode:

First-line therapy in T2D | With Prof. David Matthews
Category: Health
Duration: 00:13:44
Publish Date: 2021-11-23 05:00:00
Description:

2019 saw a dramatic change to ESC guidelines for type 2 diabetes, with SGLT2 inhibitor or GLP-1 agonist monotherapy recommended at first line in most patients. The announcement launched a debate in the diabetes community about the data behind this decision. Prof. David Matthews joins us this week to discuss what has changed since the guideline publication, and whether we are any closer to a consensus on these points.

We’ve got a new website! Find it at diabetes.knowledgeintopractice.com, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (@dkipractice) or connect on LinkedIn. 

References:

Cosentino F et al. Eur Heart J. 2020 Jan 7;41(2):255-323

American Diabetes Association. Diabetes Care. 2021;44(Supplement 1)

Marx N, et al. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol. 2021 Jan;9(1):46-52

Disclosures:

Prof. David Matthews declares the following: 

Steering committee FOCUS. Advisory Board Semaglutide - Novo Nordisk

Chair of steering committee, VERIFY trial - Novartis

Co-chair of CANVAS and CANVAS-R trials - Janssen

Servier support our Tseu fellows programme in Oxford - Servier

All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.
Total Play: 0